Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
Active, not recruiting · NCT04517851 · Registry updated 2026-06-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm, primary myelofibrosis | Active, not recruiting | Phase 2 | 2026-06-11 | NCT04517851 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| M.D. Anderson Cancer Center | 1145 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| M D Anderson Cancer Center | Houston | United States | 667 |